Compare Abeona Therapeutics Inc (ABEO) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while YieldMax COIN Option Income Strategy ETF trades at $19.9. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | CONY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $103.20 |
52-Week Low | $4.17 | $18.43 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CONY trades at $20.80, up 1.96% today, amid a bearish technical signal with resistance at $21-$22. The ETF's financial ratios are not disclosed, but it generates weekly dividends, with recent payouts ranging from $0.24 to $0.56. News highlights YieldMax's distribution announcements, though articles warn of underlying declines despite high yields.
The outlook is cautious due to bearish technicals and concerns over sustainability of high distributions. Risks include volatility from options strategies and potential capital erosion. Analyst sentiment is mixed, with no consensus ratings available, suggesting careful evaluation for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
